CERo Therapeutics (CERO) Stock Price, News & Analysis

Company Overview

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Key Stats

• Today's Range: $0.08 to $0.09
• 50-Day Range: $0.08 to $0.26
• 52-Week Range: $0.07 to $12.80
• Volume: 545,252 shs
• Average Volume: 2.53 million shs
• Market Capitalization: $4.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CERO Stock Analysis - Frequently Asked Questions

How have CERO shares performed this year?

CERo Therapeutics' stock was trading at $4.78 at the start of the year. Since then, CERO stock has decreased by 98.3% and is now trading at $0.0834.
View the best growth stocks for 2024 here.

How were CERo Therapeutics' earnings last quarter?

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.33) earnings per share (EPS) for the quarter.

How do I buy shares of CERo Therapeutics?

Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/14/2024
• Today: 9/17/2024
• Next Earnings (Estimated): 11/13/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CERO
• Previous Symbol: NASDAQ:CERO
• CUSIP: N/A
• CIK: 1870404
• Web: www.cero.bio
• Phone: 215-731-9450
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -67.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.59) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 50,740,000
• Free Float: 12,682,000
• Market Cap: $4.23 million
• Optionable: N/A
• Beta: -0.48